Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tonix Pharmaceuticals Holding Corp. - Common Stock (NQ:TNXP)

13.70 +0.42 (+3.13%)
Streaming Delayed Price Updated: 3:28 PM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 240,515
Open 13.26
Bid (Size) 13.65 (400)
Ask (Size) 13.71 (600)
Prev. Close 13.28
Today's Range 13.02 - 13.86
52wk Range 11.60 - 69.97
Shares Outstanding 11,776,542
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in Two May Investor Conferences
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q1 2026 Results, Highlights TONMYA Commercial Growth and Pipeline Progress
Via Investor Brand Network

Performance

YTD
-17.3%
-17.3%
1 Month
+5.5%
+5.5%
3 Month
-13.9%
-13.9%
6 Month
-21.9%
-21.9%
1 Year
-28.6%
-28.6%

More News

Read More
Tonix Pharmaceuticals (NASDAQ:TNXP) Beats Revenue Estimates in First Full Quarter of TONMYA Sales ↗
Via Chartmill
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Secures GPO Agreement Covering 35 Million Lives for TONMYA
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data and Plans Phase 2 Study for Lyme Disease Prevention Candidate
Via Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Highlights Preclinical Immuno-Oncology Data At AACR 2026
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Publication of TONMYA Pharmacokinetic Study in Peer-Reviewed Journal
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Phase 1 Data for Lyme Disease Candidate TNX-4800, Plans Phase 2 Study
Via Investor Brand Network
News headline image
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action? ↗
Via Benzinga
Topics Regulatory Compliance
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports Q4 and Full-Year 2025 Results, Highlights Launch of TONMYA(TM)
Via Investor Brand Network
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
TNXP Stock Rises Premarket: Investors Cheer Early Traction For Fibromyalgia Drug Despite Weak Q4 Print ↗
Via Stocktwits
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for March 11th & 12th
From Virtual Investor Conferences
Via GlobeNewswire
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents TONMYA Data at International Fibromyalgia Congress
Via Investor Brand Network
BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces Peer-Reviewed Publication Highlighting Pharmacokinetics of TONMYA(TM) Sublingual Tablets
Via Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Tonmya Data at 2026 AAPM PainConnect Annual Meeting
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present Tonmya Data at 2026 AAPM PainConnect Annual Meeting
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Approved to Transfer Listing to Nasdaq Global Select Market
Via Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Participate in March Investor Conferences
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Phase 3 Data for TONMYA(TM) in Fibromyalgia at Non-Opioid Pain Summit
Via Investor Brand Network
BioMedNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at January Investor Conferences
Via Investor Brand Network
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) to Present at January Investor Conferences
Via Investor Brand Network
News headline image
Tonix Pharmaceuticals To Meet With FDA In 2026 To Advance Experimental Lyme Disease Prevention Drug ↗
Via Stocktwits
InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Provides Update on TNX-4800 Lyme Disease Prophylaxis Program
Via Investor Brand Network
TinyGemsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Announces $20 Million Registered Direct Offering with Point72
Via Investor Brand Network

Frequently Asked Questions

Is Tonix Pharmaceuticals Holding Corp. - Common Stock publicly traded?
Yes, Tonix Pharmaceuticals Holding Corp. - Common Stock is publicly traded.
What exchange does Tonix Pharmaceuticals Holding Corp. - Common Stock trade on?
Tonix Pharmaceuticals Holding Corp. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Tonix Pharmaceuticals Holding Corp. - Common Stock?
The ticker symbol for Tonix Pharmaceuticals Holding Corp. - Common Stock is TNXP on the Nasdaq Stock Market
What is the current price of Tonix Pharmaceuticals Holding Corp. - Common Stock?
The current price of Tonix Pharmaceuticals Holding Corp. - Common Stock is 13.70
When was Tonix Pharmaceuticals Holding Corp. - Common Stock last traded?
The last trade of Tonix Pharmaceuticals Holding Corp. - Common Stock was at 05/13/26 03:28 PM ET
What is the market capitalization of Tonix Pharmaceuticals Holding Corp. - Common Stock?
The market capitalization of Tonix Pharmaceuticals Holding Corp. - Common Stock is 161.28M
How many shares of Tonix Pharmaceuticals Holding Corp. - Common Stock are outstanding?
Tonix Pharmaceuticals Holding Corp. - Common Stock has 161M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.